Search Result

Results for "

dyslipidemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Acyltransferase (1) Adenosine Receptor (1) Apical Sodium-Dependent Bile Acid Transporter (2) Apoptosis (1) Autophagy (1) Bacterial (1) Fatty Acid Synthase (FASN) (1) GPR109A (2) HMG-CoA Reductase (HMGCR) (1) HSV (2) Interleukin Related (2) Microsomal Triglyceride Transfer Protein (MTP) (1) PCSK9 (1) PPAR (12) SARS-CoV (1) Stearoyl-CoA Desaturase (SCD) (1) Thyroid Hormone Receptor (2) TNF Receptor (2) Virus Protease (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (4) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (29)

By Targets:

11β-HSD (1)

Acyltransferase (1)

Adenosine Receptor (1)

Apical Sodium-Dependent Bile Acid Transporter (2)

Apoptosis (1)

Autophagy (1)

Bacterial (1)

Fatty Acid Synthase (FASN) (1)

GPR109A (2)

HMG-CoA Reductase (HMGCR) (1)

HSV (2)

Interleukin Related (2)

Microsomal Triglyceride Transfer Protein (MTP) (1)

PCSK9 (1)

PPAR (12)

SARS-CoV (1)

Stearoyl-CoA Desaturase (SCD) (1)

Thyroid Hormone Receptor (2)

TNF Receptor (2)

Virus Protease (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (29)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106278

GW 590735	PPAR	Metabolic Disease
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-106011

SLX-4090	Others	Metabolic Disease
SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC₅₀ of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia .

HY-N8495

4'-Hydroxyflavanone	Others	Metabolic Disease
4'-Hydroxyflavanone is an inhibitor of SREBP maturation and lipid synthesis. 4'-Hydroxyflavanone is a synthetic analogue of flavanone, has potential for hepatic steatosis and dyslipidemia research .

HY-16434

DGAT1-IN-3	Acyltransferase	Metabolic Disease
DGAT1-IN-3 is a potent, selective and orally bioavailable inhibitor of DGAT-1, with IC₅₀s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. DGAT1-IN-3 could be used to research of obesity, dyslipidemia, and metabolic syndrome .

HY-139077

SCD1 inhibitor-3	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Cancer
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer .

HY-136584

2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid	Others	Cardiovascular Disease Metabolic Disease
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9. 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders .

HY-125351

SPT-IN-1	Others	Metabolic Disease
SPT-IN-1 (compound 1) is an orally active and potent SPT (serine palmitoyl transferase) inhibitor, with an IC₅₀ of 5.19 nM for hSPT1. SPT-IN-1 can be used for type 2 diabetes and dyslipidemia research .

HY-119220

Granotapide JTT-130	Microsomal Triglyceride Transfer Protein (MTP)	Metabolic Disease
Granotapide (JTT-130) is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces absorption of cholesterol and triglycerides through inhibition of MTP. Granotapide can be used for the research of dyslipidemia .

HY-120886

GW 2433	PPAR	Metabolic Disease
GW 2433 is a dual PPARα and PPARδ agonist. GW 2433 has the potential for the study of type II diabetes and dyslipidemia .

HY-111074

DB12055 MK-0767 analog	SARS-CoV	Infection Metabolic Disease
DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus .

HY-121542

PPARδ agonist 10	PPAR	Metabolic Disease
PPARδ agonist 10 (compound 7) is an orally active, selective, and partial agonist of PPARδ, with EC₅₀ values of 0.053 μM and 0.30 µM for hPPARδ(LBD)-GAL4 and mPPARδ, respectively. PPARδ agonist 10 is a partial PPARδ agonist in transactivation assay but a full agonist on free fatty acids (FFA) oxidation in muscle cells both in vitro and in vivo. PPARδ agonist 10 can be used for dyslipidemia research .

HY-153451

PCSK9-IN-15	PCSK9	Metabolic Disease
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, K_D <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .

HY-B1268

Docusate Sodium 1 Publications Verification Dioctyl sulfosuccinate sodium salt	HSV	Others
Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .

HY-B1268R

Docusate Sodium (Standard)	HSV	Others
Docusate (Sodium) (Standard) is the analytical standard of Docusate (Sodium). This product is intended for research and analytical applications. Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .

HY-119248

KRP-297 MK-0767	PPAR	Metabolic Disease
KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.

HY-B0589H

Atorvastatin strontium	HMG-CoA Reductase (HMGCR) Autophagy	Cardiovascular Disease
Strontium atorvastatin is a cholesterol-lowering drug with activity in ameliorating cardiovascular disease-related events. Strontium atorvastatin exerts its biological activity by inhibiting HMG-CoA reductase in liver tissue. Strontium atorvastatin is also used to suppress dyslipidemia .

HY-17445

Muraglitazar BMS-298585	PPAR	Metabolic Disease
Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC₅₀ = 320 nM) and PPARγ(EC₅₀ = 110 nM) .

HY-146997

TRβ agonist 1	Thyroid Hormone Receptor	Metabolic Disease
TRβ agonist 1 is a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, with an EC₅₀ value of 21 nM. TRβ agonist 1 can be used for researching dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) .

HY-143239

PPARα/γ agonist 1	PPAR	Metabolic Disease
PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC₅₀ values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-115357

BMS711939	PPAR	Metabolic Disease
BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC₅₀ of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .

HY-120943

K-111 BM 17.0744	PPAR	Metabolic Disease
K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome .

HY-162026

11β-HSD1-IN-14	11β-HSD	Metabolic Disease
11β-HSD1-IN-14 (Compound 17) is a selective inhibitor for 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1), with IC₅₀ of 74 nM for human HSD1, and 603 nM for HSD1 expressed HEK293 cell .

HY-106278A

GW 590735 sodium	PPAR	Metabolic Disease
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .

HY-15790H

(S)-Elobixibat (S)-A 3309; (S)-AZD 7806	Apical Sodium-Dependent Bile Acid Transporter TNF Receptor Interleukin Related	Metabolic Disease Inflammation/Immunology
(S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .

HY-19522

Seladelpar MBX-8025; RWJ-800025	PPAR	Metabolic Disease
Seladelpar (MBX-8025) is an orally active, potent (50% effect concentration EC₅₀ 2 nM), and specific PPAR-δ agonist .

HY-19522B

Seladelpar (lysine) MBX-8025 (lysine)	PPAR	Metabolic Disease
Seladelpar lysine is an orally active, potent (50% effect concentration EC₅₀ 2 nM), and specific PPAR-δ agonist .

HY-15790

Elobixibat A 3309; AZD 7806	Apical Sodium-Dependent Bile Acid Transporter Interleukin Related TNF Receptor	Metabolic Disease Inflammation/Immunology
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC₅₀ value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .

HY-119222

GSK256073 2 Publications Verification	GPR109A	Metabolic Disease
GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC₅₀ of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2

HY-119222A

GSK256073 tris	GPR109A	Metabolic Disease
GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC₅₀ of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2

HY-19522C

Seladelpar Lysine dihydrate MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate	PPAR	Metabolic Disease
Seladelpar Lysine dihydrate (MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate) is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC₅₀ of 2 nM. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .

HY-117912

TRC210258	Others	Cardiovascular Disease
TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .

HY-19842

GS-9667 CVT 3619	Adenosine Receptor	Cardiovascular Disease Metabolic Disease
GS-9667 (CVT 3619), a novel N ⁶-5'-substituted adenosine analog, is a selective, partial agonist of the A₁ adenosine receptor (A₁AdoR). GS-9667 binds to adipocyte membranes with high (K_H=14 nM) and low (K_L=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC₅₀ values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) .

HY-N0288

Lycorine 10+ Cited Publications	Fatty Acid Synthase (FASN) Virus Protease Bacterial Apoptosis	Inflammation/Immunology Cancer
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription . Lycorine is also a melanoma vasculogenic inhibitor . Lycorine can be used for the study of prostate cancer and metabolic diseases .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	2,516 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 2,516 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

2,516 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,516 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

4'-Hydroxyflavanone	Flavonoids Monophenols Microorganisms Classification of Application Fields Flavonones Source classification Phenols Metabolic Disease Disease Research Fields	Others
4'-Hydroxyflavanone is an inhibitor of SREBP maturation and lipid synthesis. 4'-Hydroxyflavanone is a synthetic analogue of flavanone, has potential for hepatic steatosis and dyslipidemia research .

Lycorine 10+ Cited Publications	Alkaloids Structural Classification other families Pyrrole Alkaloids Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Amaryllidaceae	Fatty Acid Synthase (FASN) Virus Protease Bacterial Apoptosis
Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription . Lycorine is also a melanoma vasculogenic inhibitor . Lycorine can be used for the study of prostate cancer and metabolic diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks